ArticleNews reportPHN-05622026-11-02 05:03 CT

DataMEDS AI unit signs supply deal for six FDA advisory-recommended peptides

Source · StreetInsider

TLDR

DataMEDS AI announced that its pharmacy subsidiary Corexa Health signed a commercial supply agreement covering six peptides. The article reports that an FDA advisory committee recommended the peptides in July 2026, and the company says it intends to begin dispensing compounded prescriptions in November 2026.

01—Key points

01The agreement covers BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax.
02The reported recommendations came from the FDA’s Pharmacy Compounding Advisory Committee at its July 23–24, 2026 meeting.
03DataMEDS says it plans to collect and report safety data through its Health Lives Here app under an HHS enforcement discretion policy.

Why it matters Editorial

The announcement describes a commercial expansion into peptide compounding alongside company plans for safety-data reporting.

Read the original at StreetInsider↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.